Business
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilizationBROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatm
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EohHW56rTadgndYE9QH9_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"text","content":"Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization","length":121,"tagName":"p"},{"type":"text","content":"BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion’s board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was agreed to as an inducement material to Mr. Keefe entering into employment with Aclarion. The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635(c)(4).","length":883,"tagName":"p"},{"type":"text","content":"The option has an exercise price of $3.20 per share, which was equal to the closing price of Aclarion's common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date, and the remainder vest in equal monthly installments over the next three years, subject to the new employee's continued service with the Company. The stock option has a 10-year term and is subject to the terms and conditions of an inducement stock option agreement covering the grant.","length":521,"tagName":"p"},{"type":"text","content":"About Aclarion, Inc. ","length":20,"tagName":"p"},{"type":"text","content":"Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ...